Progestins as a Contributing Factor to Hepatocellular Adenoma: A Case Series and Literature Review
No Preview Available
Citations
Scopus:
Altmetric:
Altmetric::
Associated Records
Authors
File Licence
Editors
Date
2024-04
Source Title
Journal of Pediatric and Adolescent Gynecology
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Melbourne Authors
Affiliation
Paediatrics (RCH)
Document Type
Journal Article
Subject Code
Citation
Moussaoui, D. & Grover, S. R. (2024). Progestins as a Contributing Factor to Hepatocellular Adenoma: A Case Series and Literature Review. Journal of Pediatric and Adolescent Gynecology, 37 (2), pp.184-191. https://doi.org/10.1016/j.jpag.2023.11.003.
Access Status
Open Access
Access URL
Open Access URL
Open Access at PMC
Linked Resource URL
NHMRC Grant Code
ARC Grant Code
Description
Abstract
STUDY OBJECTIVE: To explore the role of progestins as potential contributing factors for the development of hepatocellular adenoma (HA) METHODS: We describe 3 cases of adolescents and young adults who developed HA while on norethindrone (NET), as well as their management. In addition, we provide a comprehensive literature review on the association between progestins and HA. RESULTS: Since 1983, 16 cases of HA in patients on progestins have been reported. Ten patients were on NET and 5 on a prodrug of NET (4 on norethindrone acetate [NETA] and 1 on lynestrenol). One individual had a norgestrel implant. Eight subsequently ceased all hormones: 4 experienced a size reduction, and 3 had complete resolution of their HA. Among our patients, 1 ceased NET and instead had a levonorgestrel intrauterine device inserted, and another swapped from NET to oral medroxyprogesterone acetate. Both experienced complete resolution of their HA. The third ceased NET and underwent a hysterectomy, with size reduction of her HA. CONCLUSION: These cases and the literature review suggest an association between progestin exposure, in particular NET and its prodrugs, and the development of HA. The pathophysiology is unknown but may include peripheral conversion of NET and NETA to ethinyl estradiol or a specific action of 19-nortestosterone derivatives on hepatocytes, especially those with higher systemic doses compared with the levonorgestrel intrauterine device. There are no case reports relating to other forms of progestins, such as 17-hydroxyprogesterone, which may be important when considering alternative therapeutic options in females requiring effective menstrual management who have comorbidities.